ID   CAV1_RABIT              Reviewed;         178 AA.
AC   Q09YN6;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 1.
DT   07-APR-2021, entry version 106.
DE   RecName: Full=Caveolin-1;
GN   Name=CAV1;
OS   Oryctolagus cuniculus (Rabbit).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Lagomorpha; Leporidae; Oryctolagus.
OX   NCBI_TaxID=9986;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Antonellis A., Ayele K., Benjamin B., Blakesley R.W., Boakye A.,
RA   Bouffard G.G., Brinkley C., Brooks S., Chu G., Coleman H., Engle J.,
RA   Gestole M., Greene A., Guan X., Gupta J., Haghighi P., Han J., Hansen N.,
RA   Ho S.-L., Hu P., Hunter G., Hurle B., Idol J.R., Kwong P., Laric P.,
RA   Larson S., Lee-Lin S.-Q., Legaspi R., Madden M., Maduro Q.L., Maduro V.B.,
RA   Margulies E.H., Masiello C., Maskeri B., McDowell J., Mojidi H.A.,
RA   Mullikin J.C., Oestreicher J.S., Park M., Portnoy M.E., Prasad A., Puri O.,
RA   Reddix-Dugue N., Schandler K., Schueler M.G., Sison C., Stantripop S.,
RA   Stephen E., Taye A., Thomas J.W., Thomas P.J., Tsipouri V., Ung L.,
RA   Vogt J.L., Wetherby K.D., Young A., Green E.D.;
RT   "NISC comparative sequencing initiative.";
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: May act as a scaffolding protein within caveolar membranes.
CC       Forms a stable heterooligomeric complex with CAV2 that targets to lipid
CC       rafts and drives caveolae formation. Mediates the recruitment of CAVIN
CC       proteins (CAVIN1/2/3/4) to the caveolae (By similarity). Interacts
CC       directly with G-protein alpha subunits and can functionally regulate
CC       their activity (By similarity). Involved in the costimulatory signal
CC       essential for T-cell receptor (TCR)-mediated T-cell activation. Its
CC       binding to DPP4 induces T-cell proliferation and NF-kappa-B activation
CC       in a T-cell receptor/CD3-dependent manner (By similarity). Recruits
CC       CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling
CC       through the Wnt pathway (By similarity). Negatively regulates TGFB1-
CC       mediated activation of SMAD2/3 by mediating the internalization of
CC       TGFBR1 from membrane rafts leading to its subsequent degradation (By
CC       similarity). {ECO:0000250|UniProtKB:P49817,
CC       ECO:0000250|UniProtKB:Q03135}.
CC   -!- SUBUNIT: Homooligomer. Interacts (via the N-terminus) with DPP4; the
CC       interaction is direct. Forms a stable heterooligomeric complex with
CC       CAV2 that targets to lipid rafts and drives caveolae formation.
CC       Interacts with PACSIN2; this interaction induces membrane tubulation
CC       (By similarity). Interacts with BMX, BTK, CTNNB1, CDH1, GLIPR2, JUP,
CC       NOSTRIN, SNAP25 and STX1A. Interacts with SLC7A9. Interacts with
CC       TGFBR1. Interacts with CAVIN3 (via leucine-zipper domain) in a
CC       cholesterol-sensitive manner. Interacts with CAVIN1. Interacts with
CC       EHD2 in a cholesterol-dependent manner. Forms a ternary complex with
CC       UBXN6 and VCP; mediates CAV1 targeting to lysosomes for degradation.
CC       Interacts with ABCG1; this interaction regulates ABCG1-mediated
CC       cholesterol efflux (By similarity). Interacts with NEU3; this
CC       interaction enhances NEU3 sialidase activity within caveola. Interacts
CC       (via C-terminus) with SPRY1, SPRY2 (via C-terminus), SPRY3, and SPRY4
CC       (By similarity). {ECO:0000250|UniProtKB:P41350,
CC       ECO:0000250|UniProtKB:P49817, ECO:0000250|UniProtKB:Q03135,
CC       ECO:0000250|UniProtKB:Q2IBA5}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}. Cell membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}. Membrane, caveola
CC       {ECO:0000250|UniProtKB:P49817}; Peripheral membrane protein
CC       {ECO:0000250}. Membrane raft {ECO:0000250|UniProtKB:Q03135}.
CC       Note=Colocalized with DPP4 in membrane rafts. Potential hairpin-like
CC       structure in the membrane. Membrane protein of caveolae (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated at Tyr-14 by ABL1 in response to oxidative stress.
CC       {ECO:0000250|UniProtKB:Q03135}.
CC   -!- PTM: Ubiquitinated. Undergo monoubiquitination and multi- and/or
CC       polyubiquitination. Monoubiquitination of N-terminal lysines promotes
CC       integration in a ternary complex with UBXN6 and VCP which promotes
CC       oligomeric CAV1 targeting to lysosomes for degradation.
CC       {ECO:0000250|UniProtKB:Q03135}.
CC   -!- SIMILARITY: Belongs to the caveolin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DP000006; AAY89011.1; -; Genomic_DNA.
DR   RefSeq; NP_001104542.1; NM_001111072.1.
DR   SMR; Q09YN6; -.
DR   STRING; 9986.ENSOCUP00000012485; -.
DR   Ensembl; ENSOCUT00000014518; ENSOCUP00000012485; ENSOCUG00000014520.
DR   GeneID; 100008837; -.
DR   KEGG; ocu:100008837; -.
DR   CTD; 857; -.
DR   eggNOG; ENOG502QUK5; Eukaryota.
DR   GeneTree; ENSGT00950000183006; -.
DR   HOGENOM; CLU_102582_0_0_1; -.
DR   InParanoid; Q09YN6; -.
DR   OMA; SIRINMQ; -.
DR   OrthoDB; 1468974at2759; -.
DR   TreeFam; TF315736; -.
DR   Proteomes; UP000001811; Chromosome 7.
DR   Bgee; ENSOCUG00000014520; Expressed in left lung and 16 other tissues.
DR   GO; GO:0002080; C:acrosomal membrane; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; ISS:UniProtKB.
DR   GO; GO:0002095; C:caveolar macromolecular signaling complex; IEA:Ensembl.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0005929; C:cilium; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IEA:Ensembl.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0051117; F:ATPase binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0070320; F:inward rectifier potassium channel inhibitor activity; IEA:Ensembl.
DR   GO; GO:0044325; F:ion channel binding; IEA:Ensembl.
DR   GO; GO:0050998; F:nitric-oxide synthase binding; IEA:Ensembl.
DR   GO; GO:0016504; F:peptidase activator activity; IEA:Ensembl.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; IEA:Ensembl.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl.
DR   GO; GO:0031267; F:small GTPase binding; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0086098; P:angiotensin-activated signaling pathway involved in heart process; IEA:Ensembl.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0071711; P:basement membrane organization; IEA:Ensembl.
DR   GO; GO:0006816; P:calcium ion transport; IEA:Ensembl.
DR   GO; GO:0070836; P:caveola assembly; IEA:Ensembl.
DR   GO; GO:0072584; P:caveolin-mediated endocytosis; IEA:Ensembl.
DR   GO; GO:0071360; P:cellular response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0042632; P:cholesterol homeostasis; IEA:Ensembl.
DR   GO; GO:0000188; P:inactivation of MAPK activity; IEA:Ensembl.
DR   GO; GO:0038016; P:insulin receptor internalization; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0060056; P:mammary gland involution; IEA:Ensembl.
DR   GO; GO:0051899; P:membrane depolarization; IEA:Ensembl.
DR   GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0001960; P:negative regulation of cytokine-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:1903609; P:negative regulation of inward rectifier potassium channel activity; IEA:Ensembl.
DR   GO; GO:0060546; P:negative regulation of necroptotic process; IEA:Ensembl.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051001; P:negative regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:1900085; P:negative regulation of peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0048550; P:negative regulation of pinocytosis; IEA:Ensembl.
DR   GO; GO:0032091; P:negative regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IEA:Ensembl.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0042532; P:negative regulation of tyrosine phosphorylation of STAT protein; IEA:Ensembl.
DR   GO; GO:0033484; P:nitric oxide homeostasis; IEA:Ensembl.
DR   GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0060355; P:positive regulation of cell adhesion molecule production; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IEA:Ensembl.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; IEA:Ensembl.
DR   GO; GO:1903071; P:positive regulation of ER-associated ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:1903598; P:positive regulation of gap junction assembly; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0032092; P:positive regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0034141; P:positive regulation of toll-like receptor 3 signaling pathway; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0010608; P:posttranscriptional regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0015031; P:protein transport; IEA:Ensembl.
DR   GO; GO:0031623; P:receptor internalization; ISS:UniProtKB.
DR   GO; GO:2000286; P:receptor internalization involved in canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0019065; P:receptor-mediated endocytosis of virus by host cell; IEA:Ensembl.
DR   GO; GO:0030193; P:regulation of blood coagulation; IEA:Ensembl.
DR   GO; GO:1901844; P:regulation of cell communication by electrical coupling involved in cardiac conduction; IEA:Ensembl.
DR   GO; GO:2000535; P:regulation of entry of bacterium into host cell; IEA:Ensembl.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IEA:Ensembl.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IEA:Ensembl.
DR   GO; GO:0098903; P:regulation of membrane repolarization during action potential; IEA:Ensembl.
DR   GO; GO:1900027; P:regulation of ruffle assembly; IEA:Ensembl.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0003057; P:regulation of the force of heart contraction by chemical signal; IEA:Ensembl.
DR   GO; GO:0098911; P:regulation of ventricular cardiac muscle cell action potential; IEA:Ensembl.
DR   GO; GO:0009617; P:response to bacterium; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IEA:Ensembl.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0031295; P:T cell costimulation; ISS:UniProtKB.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   GO; GO:0042310; P:vasoconstriction; IEA:Ensembl.
DR   InterPro; IPR015504; CAV-1.
DR   InterPro; IPR001612; Caveolin.
DR   InterPro; IPR018361; Caveolin_CS.
DR   PANTHER; PTHR10844; PTHR10844; 1.
DR   PANTHER; PTHR10844:SF18; PTHR10844:SF18; 1.
DR   Pfam; PF01146; Caveolin; 1.
DR   PROSITE; PS01210; CAVEOLIN; 1.
PE   3: Inferred from homology;
KW   Acetylation; Cell membrane; Golgi apparatus; Isopeptide bond; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Reference proteome; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   CHAIN           2..178
FT                   /note="Caveolin-1"
FT                   /id="PRO_0000260373"
FT   TOPO_DOM        2..104
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        105..125
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        126..178
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          2..94
FT                   /note="Required for homooligomerization"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   REGION          82..94
FT                   /note="Interaction with CAVIN3"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   REGION          131..142
FT                   /note="Interacts with SPRY1, SPRY2, SPRY3 and SPRY4"
FT                   /evidence="ECO:0000250|UniProtKB:P49817"
FT   REGION          149..160
FT                   /note="Interacts with SPRY1, SPRY2, and SPRY4"
FT                   /evidence="ECO:0000250|UniProtKB:P49817"
FT   REGION          167..178
FT                   /note="Interacts with SPRY1, SPRY2, SPRY3 and SPRY4"
FT                   /evidence="ECO:0000250|UniProtKB:P49817"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P41350"
FT   MOD_RES         5
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   MOD_RES         6
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   MOD_RES         9
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P49817"
FT   MOD_RES         14
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000250|UniProtKB:P49817"
FT   MOD_RES         25
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   LIPID           133
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           143
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           156
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        5
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   CROSSLNK        26
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   CROSSLNK        30
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   CROSSLNK        39
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   CROSSLNK        47
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
FT   CROSSLNK        57
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q03135"
SQ   SEQUENCE   178 AA;  20568 MW;  4D4BFE8BD0614FD2 CRC64;
     MSGGKYVDSE GHLYTVPIRE QGNIYKPNNK AMADEVNEKQ VYDAHTKEID LVNRDPKHLN
     DDVVKIDFED VIAEPEGTHS FDGIWKASFT TFTVTKYWFY RLLSTIFGIP MALIWGIYFA
     ILSFLHIWAV VPCIKSFLIE IQCISRVYSI YVHTFCDPLF EAIGKIFSNV RISMQKEI
//
